MARINOMED BIOTECH AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.4 EUR | +0.40% |
|
-2.36% | -58.53% |
| 22/05 | Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024 | |
| 21/05 | Marinomed Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 18.19M 19.48M 1.62B | Sales 2025 * | 24.58M 26.33M 2.2B | Capitalization | 19.41M 20.79M 1.73B |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 2M 2.14M 179M | EV / Sales 2024 * | 2.01 x |
| Net Debt 2024 * | 17.11M 18.33M 1.53B | Net Debt 2025 * | 13.53M 14.49M 1.21B | EV / Sales 2025 * | 1.34 x |
| P/E ratio 2024 * |
40.6
x | P/E ratio 2025 * |
9.16
x | Employees | 44 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Marinomed Biotech AG
More press releases
More news
| 1 day | +0.40% | ||
| 1 week | -2.36% | ||
| Current month | -15.36% | ||
| 1 month | -12.06% | ||
| 3 months | -37.37% | ||
| 6 months | -60.13% | ||
| Current year | -58.53% |
1 week
12.35
12.65
1 month
12.3514.65
Current year
12.3530.80
1 year
12.3543.90
3 years
12.35126.00
5 years
12.35148.00
10 years
12.35148.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 55 | 01/06/01 | |
| Founder | 56 | 01/06/01 | |
Pascal Schmidt
DFI | Director of Finance/CFO | 52 | 01/18/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 58 | 01/08/01 | |
Brigitte Ederer
BRD | Director/Board Member | 68 | 21/18/21 |
| Director/Board Member | - | 15/22/15 |
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 12.4 | +0.40% |
| 27/24/27 | 12.35 | -0.40% |
| 26/24/26 | 12.4 | -1.59% |
| 25/24/25 | 12.6 | -0.40% |
| 24/24/24 | 12.65 | +0.40% |
Delayed Quote Deutsche Boerse AG, June 28, 2024 at 11:31 am IST
More quotes
Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.
Sector
Pharmaceuticals
Calendar
20/08/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.6
EUR
Average target price
63
EUR
Spread / Average Target
+400.00%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.99% | 94.76B | |
| -4.34% | 37.58B | |
| -10.41% | 33.3B | |
| +75.79% | 27.92B | |
| -14.61% | 15.85B | |
| -3.46% | 13.79B | |
| -12.31% | 11.51B | |
| +184.77% | 10.9B | |
| -54.13% | 9.27B |
- Stock Market
- Equities
- MARI Stock
- 93Z Stock
